Skip to main content

GH Research PLC (GHRS)

NASDAQ: GHRS · IEX Real-Time Price · USD
19.32 -1.82 (-8.61%)
Sep 20, 2021 9:48 AM EDT - Market open
Market Cap976.06M
Revenue (ttm)n/a
Net Income (ttm)-1.58M
Shares Out50.52M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume26,623
Open20.33
Previous Close21.14
Day's Range19.27 - 20.80
52-Week Range15.08 - 26.91
Betan/a
Analystsn/a
Price Target32.00 (+65.6%)
Est. Earnings Daten/a

About GHRS

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Patients with Major Depressive Disorder, or MDD, who have not adequately responded to adequate therapy clearly have harder-to-treat depression, generally referred to as TRD. There is no consensus definition for ...

IndustryBiotechnology
IPO DateJun 25, 2021
CEOTheis Terwey
Employees8
Stock ExchangeNASDAQ
Ticker SymbolGHRS
Full Company Profile

Financial Performance

Financial Statements

News

GH Research PLC Announces Pricing of Initial Public Offering

GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders,...

2 months ago - PRNewswire

GH Research PLC IPO Registration Document (S-1)

GH Research PLC has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC